Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113587 | 0.85 | KMT2A (0.71) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL228921 | 0.84 | HSD11B1 (0.63) | KMT2APOLBMEN1 | |
| SCHEMBL4235957 | 0.84 | MGLL (0.56) | GPR119KMT2ASLC18A3PTPN2PTPN1 | |
| SCHEMBL473345 | 0.84 | STS (0.67) | KMT2ASTSMEN1 | |
| SCHEMBL24833605 | 0.84 | MGLL (0.56) | GPR119KMT2ASLC18A3PTPN2PTPN1 | |
| SCHEMBL441012 | 0.84 | KDM4E (0.62) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL16432195 | 0.83 | KMT2A (0.58) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL4240126 | 0.83 | POLB (0.69) | GPR119KMT2ASTSPOLBMEN1 | |
| SCHEMBL18824369 | 0.83 | KMT2A (0.58) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL4777861 | 0.83 | GPR119 (0.69) | GPR119KMT2APTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | GPR119 207/4885KMT2A 4728/4885SLC18A3 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.